Number of patients achieving or not the American College of Rheumatology 50% improvement (ACR50) response rates at week 24 in biological and placebo groups for all included studies (for IR-MTX and IR-anti-TNF RA)
| ACR50 response rate, no. patients (%) | ||||
|---|---|---|---|---|
| Study | Arms | Achieved | Not achieved | Total |
| RA with inadequate response to MTX (IR-MTX RA) | ||||
| ATTEST6 | Abatacept+MTX | 63 (40.4%) | 93 (59.6%) | 156 |
| Placebo+MTX | 22 (20%) | 88 (80%) | 110 | |
| ATTEST19 | Abatacept+MTX | 169 (40%) | 255 (60%) | 424 |
| Placebo+MTX | 36 (17%) | 178 (83%) | 214 | |
| ATTEST18 | Abatacept+MTX | 42 (36.6%) | 73 (63.4%) | 115 |
| Placebo+MTX | 14 (11.8%) | 105 (88.2%) | 119 | |
| ATTEST15 | Rituximab+MTX | 17 (42.5%) | 23 (57.5%) | 40 |
| Placebo+MTX | 5 (12.5%) | 35 (87.5%) | 40 | |
| SERENE17 | Rituximab+MTX | 44 (25.6%) | 128 (74.4%) | 172 |
| Placebo+MTX | 15 (8.7%) | 157 (91.3%) | 172 | |
| DANCER*16 | Rituximab+MTX | 35 (39.3%) | 54 (60.7%) | 89 |
| Placebo+MTX | 15 (16.5%) | 76 (83.5%) | 91 | |
| OPTION20 | Tocilizumab+MTX | 90 (44%) | 115 (56%) | 205 |
| Placebo+MTX | 22 (10.8%) | 182 (89.2%) | 204 | |
| ATTEST6 | Infliximab+MTX | 61 (37%) | 104 (63%) | 165 |
| Placebo+MTX | 22 (20%) | 88 (80%) | 110 | |
| ATTRACT7 | Infliximab+MTX | 48 (28%) | 125 (72%) | 173 |
| Placebo+MTX | 4 (4.5%) | 84 (95.5%) | 88 | |
| ATTRACT8 | Etanercept+MTX | 23 (39%) | 36 (61%) | 59 |
| Placebo+MTX | 1 (3.3%) | 29 (96.7%) | 30 | |
| ARMADA9 | Adalimumab+MTX | 37 (55.2%) | 30 (44.8%) | 67 |
| Placebo+MTX | 5 (8.0%) | 57 (92%) | 62 | |
| ATTRACT11 | Adalimumab+MTX | 28 (43%) | 37 (57%) | 65 |
| Placebo+MTX | 9 (14.3%) | 54 (85.7%) | 63 | |
| ATTRACT10 | Adalimumab+MTX | 81 (39%) | 126 (61%) | 207 |
| Placebo+MTX | 19 (9.5%) | 181 (90.5%) | 200 | |
| GO-FORWARD14 | Golimumab+MTX | 33 (37%) | 56 (63%) | 89 |
| Placebo+MTX | 18 (13.5%) | 115 (86.5%) | 133 | |
| RAPID 112 | Certolizumab+MTX | 146 (37.1%) | 247 (62.9%) | 393 |
| Placebo+MTX | 15 (7.5%) | 184 (92.5%) | 199 | |
| RAPID 213 | Certolizumab+MTX | 80 (32.5%) | 166 (67.5%) | 246 |
| Placebo+MTX | 4 (3.1%) | 123 (96.9%) | 127 | |
| RA with inadequate response to anti-TNF (IR-anti-TNF RA) | ||||
| GO-AFTER†25 | Golimumab+MTX | 26 (25.2%) | 77 (74.8%) | 103 |
| Placebo+MTX | 6 (6%) | 96 (94%) | 102 | |
| ATTAIN† 23 | Abatacept+DMARD | 52 (20.%) | 206 (80%) | 258 |
| Placebo+DMARD | 5 (3.7%) | 128 (96.3%) | 133 | |
| RADIATE24 | Tocilizumab+MTX | 50 (28.6%) | 125 (71.4%) | 175 |
| Placebo+MTX | 6 (3.8%) | 153 (96.2%) | 159 | |
| REFLEX22 | Rituximab+MTX | 83 (26.8%) | 226 (73.2%) | 309 |
| Placebo+MTX | 10 (4.8%) | 198 (95.2%) | 208 | |
| DANCER‡17 | Rituximab+MTX | 7 (21.2%) | 26 (78.8%) | 33 |
| Placebo+MTX | 1 (3.2%) | 30 (96.7%) | 31 | |
↵* After exclusion of patients with prior anti-TNF treatment (data available from the firm).
↵† After exclusion of patients without concomitant DMARD.
↵‡ Including patients who received previous anti-TNF (data available from the firm).
DMARD, disease-modifying antirheumatic drug; IR, inadequate response; MTX, methotrexate; RA, rheumatoid arthritis; TNF, tumour necrosis factor.